Eleven clinical trials planned in 2024 and are likely to affect the future of Medicine presents the magazine “Nature Medicine” in its annual issue.

The use of artificial intelligence features prominently on the list, as few such tools have been tested in clinical trials.

The MARS-ED clinical trial evaluates the benefits of an artificial intelligence model to help predict 31-day mortality risk for patients who sought treatment in an emergency department.

Another trial in 150,000 patients in six UK hospitals is looking at whether artificial intelligence can analyze chest X-rays for the early diagnosis of lung cancer.

Further cancer trials highlighted by Nature Medicine include the 3-IN-THE LUNG-RUN trial, which will compare whether screening every two years for lung cancer is as effective in preventing cancer deaths as the annual exams.

The efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate, targeting HER2 breast cancer is evaluated in participants with and without brain metastasis. T

Finally, the NADINA study aims to compare the efficacy of nivolumab-ipilimumab combination immunotherapy versus adjuvant nivolumab in stage III melanoma.

The article also highlights an app that allows women who are in their second or third trimester of pregnancy and suffer from severe depression to have cognitive therapy support.

Another mental health trial will investigate the effectiveness of an intervention model for the mental health of infants aged 0-5 years living in foster care in Glasgow and London.

In the area of ​​vaccines, trials for human immunodeficiency virus vaccine and malaria vaccine for children aged 5-36 months are presented.

In addition, the STEM-PD trial is presented, where dopamine-producing neurons derived from human embryonic stem cells will be transplanted into the brains of patients aged 50-75 with moderate Parkinson’s disease.

End, the heart-1 trial is studying whether DNA base editing has potential as a treatment for resistant LDL-cholesterol lowering in patients with a genetically induced form of hypercholesterolemia.

“These are potentially exciting treatments, but only through these trials can researchers know whether they will benefit patients“, notes Ben Johnson, senior magazine editor at “Nature Medicine”.